AZD1222 vaccinees produce a robust antibody recall response to attenuate SARS-CoV-2 infection
VIRAL SHEDDING
Median ILL-D1 anti-spike-binding titers in vaccinees were similar to peak titers seen 14 days after dose 2 of AZD1222 (The kinetics and magnitude of the breakthrough anti-SARS-CoV-2 antibody response are impacted by age and vaccination status. Levels of anti-SARS-CoV-2 Median ILL-D1 nAb titers were comparable to peak titers observed 28 days after dose 2 of AZD1222 (Nucleocapsid antibodies were induced more slowly than spike-binding antibodies and were lower in overall magnitude, with higher median titers in placebo recipients versus vaccinees at ILL-D14 and ILL-D28 (Median spike-binding titers differed with increased time since second dose of primary series vaccination (Initial breakthrough SARS-CoV-2 spike-binding antibody titers are influenced by the interval since second dose primary series vaccination. Levels of anti-SARS-CoV-2 spike-binding antibodies by time since second dose of primary series vaccination. The bottom and top edges of the box indicate the first and third quartiles, the difference is the IQR, the line inside the box is the median, and the marker inside the box is the mean. The whiskers that extend from the box indicate the minimum and maximum after removing outliers (i.e., datapoints >1.5 x IQR from the box).ILL-D1 nAb responses inversely correlated with SARS-CoV-2 virologic outcomes, with low-to-moderate correlations observed for nasopharyngeal viral loads (Pearson: AZD1222 –0.137; placebo –0.445) and viral shedding titers in saliva (Pearson: AZD1222 –0.469; placebo –0.398) (Illness visit day 1 SARS-CoV-2 nAb titers display low-moderate negative correlations with SARS-CoV-2 virologic outcomes. Scatterplot analysis depicting the relationship between 